Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B

Antiviral Therapy

Volumn 9, Issue 3, 2004, Pages 325-334

  Akarca, Ulus Salih ^a   Ersoz, Galip ^a   Gunsar, Fulya ^a   Karasu, Zeki ^a   Saritas, Elif ^a   Yuce, Gul ^a   Batur, Yucel ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; HEPATITIS B(E) ANTIBODY; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DUODENUM ULCER; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE WEAKNESS; MYOSITIS; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; HEPATITIS B ANTIBODIES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; NECROSIS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 3042774559     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lok ASF & McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
2. Esteban R. Management of chronic hepatitis B: an overview. Seminars in Liver Disease 2002; 22(Suppl. 1):1-6.
3. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS & Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B; A meta-analysis. Annals of Internal Medicine 1993; 119:312-323.
4. Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, Dastoli G, Pastore G, Ideo G, Bonino F & Brunetto MR. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. American Journal of Gastroenterology 1999; 94:1366-1372.
5. Manesis EK & Hadziyannis SJ. Interferon-α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121:101-109.
6. Lok AS, Heathcote EJ & Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120:1828-1853.
7. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD & Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
8. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. Journal of Gastroenterology & Hepatology 2002; 17:409-414.
9. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K & Kumada H. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. Journal of Hepatology 2002; 37:824-830.
10. Xiong X, Flores C, Yang H, Toole JJ & Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-1673.
11. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy & Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-134.
12. Marcellin P. Advances in therapy for chronic hepatitis B. Seminars in Liver Disease 2002; 22(Suppl. 1):33-36.
13. Cherrington JM, Mulato AS, Fuller MD & Chen MS. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxyethyl]adenine in vitro. Antimicrobial Agents & Chemotherapy 1996; 40:2212-2216.
14. Delaney WE, Locarnini S & Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chemistry & Chemotherapy 2001; 12:1-35.
15. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, deMan R, McPhilips P, Johnson M, Williams R, Elias E & Schalm S. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. Journal of Hepatology 1998; 28:923-929.
16. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J & Gray DF. International Lamivudine Study Group. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562-568.
17. Schiff ER, Karayalcin S, Grimm I, Perillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhilips P, Brown N & the International Lamivudine Investigator Group. A placebo controlled study of lamivudine and interferon α-2β in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998; 28:388A.
18. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C & Francavilla A. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. Journal of Hepatology 2001; 35:805-810.
19. Santantonio T, Niro A G, Sinisi E, Gioacchino L, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A & Patore G. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. Journal of Hepatology 2002; 36:799-804.
20. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri M, Annese M, Matarazzo F, Di Stefano G & Barbarini G. Long-term efficacy of interferon α-2β and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. Journal of Hepatology 2001; 35:406-411.
21. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
22. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW & Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
23. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L & Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29:889-896.
24. Buti M, Cotrina M, Jardi R, de Castro EC, Rodriguez-Frias F, Sanchez-Avila F, Esteban R & Guardia J. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. Journal of Viral Hepatology 2001; 8:270-275.
25. Sangfelt P, Uhnoo I, Hollander A, Lindh G & Weiland O. Lamivudine and famciclovir combination therapy with or without addition of interferon-α-2β for HBeAg-positive chronic hepatitis B: a pilot study. Scandinavian Journal of Infectious Diseases 2002; 34:505-511.
26. Dikici B, Bosnak M, Bosnak V, Dagli A, Davutoglu M, Yagci RV & Haspolat K. Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatrics International 2002; 44:517-521.
27. Selimoglu MA, Aydogdu S, Unal F, Zeytinoglu A, Yuce G & Yagci RV. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatrics International 2002; 44:404-408.
28. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M & Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186-194.
29. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ & Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32(4 Pt 1):828-834.
30. Zoulim F. Evaluation of novel strategies to combat hepatitis B virus targeting wild-type and drug-resistant mutants in experimental models. Antiviral Chemistry & Chemotherapy 2001; 12(Suppl. 1):131-142.
31. Mutimer D. Hepatitis B virus antiviral drug resistance: from the laboratory to the patient. Antiviral Therapy 1998; 3:243-246.
32. Liaw YF, Chien RN, Yeh CT, Tsai SL & Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
33. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P & Schalm SW. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 1999; 30:238-243.